Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) have earned a consensus recommendation of “Hold” from the six ratings firms that are covering the company. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $24.00.

Several equities research analysts have weighed in on ATRA shares. Jefferies Group LLC set a $23.00 target price on Atara Biotherapeutics and gave the stock a “buy” rating in a research report on Monday, December 12th. Canaccord Genuity set a $47.00 target price on Atara Biotherapeutics and gave the stock a “buy” rating in a research report on Saturday, March 11th. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 4th. Finally, Citigroup Inc set a $10.00 target price on Atara Biotherapeutics and gave the stock a “sell” rating in a research report on Thursday, March 16th.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 4,800 shares of the stock in a transaction on Friday, December 23rd. The stock was sold at an average price of $15.22, for a total value of $73,056.00. Following the sale, the chief executive officer now directly owns 555,044 shares of the company’s stock, valued at $8,447,769.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Isaac E. Ciechanover sold 8,400 shares of the stock in a transaction on Friday, January 6th. The stock was sold at an average price of $16.89, for a total value of $141,876.00. Following the completion of the sale, the chief executive officer now directly owns 555,044 shares in the company, valued at $9,374,693.16. The disclosure for this sale can be found here. Insiders sold 133,195 shares of company stock worth $2,288,178 over the last ninety days. 16.10% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Arrowpoint Asset Management LLC boosted its stake in shares of Atara Biotherapeutics by 18.2% in the fourth quarter. Arrowpoint Asset Management LLC now owns 1,560,612 shares of the company’s stock worth $22,161,000 after buying an additional 240,285 shares during the last quarter. Eagle Asset Management Inc. boosted its stake in shares of Atara Biotherapeutics by 0.8% in the third quarter. Eagle Asset Management Inc. now owns 980,673 shares of the company’s stock worth $20,976,000 after buying an additional 8,081 shares during the last quarter. Neuberger Berman Group LLC boosted its stake in shares of Atara Biotherapeutics by 9.5% in the third quarter. Neuberger Berman Group LLC now owns 688,715 shares of the company’s stock worth $14,732,000 after buying an additional 59,595 shares during the last quarter. State Street Corp boosted its stake in shares of Atara Biotherapeutics by 62.8% in the fourth quarter. State Street Corp now owns 600,521 shares of the company’s stock worth $8,526,000 after buying an additional 231,541 shares during the last quarter. Finally, Artal Group S.A. boosted its stake in shares of Atara Biotherapeutics by 122.2% in the fourth quarter. Artal Group S.A. now owns 500,000 shares of the company’s stock worth $7,100,000 after buying an additional 275,000 shares during the last quarter. 77.48% of the stock is owned by institutional investors.

Atara Biotherapeutics (NASDAQ:ATRA) opened at 21.25 on Tuesday. Atara Biotherapeutics has a 1-year low of $12.45 and a 1-year high of $25.73. The firm’s 50-day moving average price is $16.27 and its 200-day moving average price is $17.10. The firm’s market cap is $618.14 million.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, March 9th. The company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.98) by $0.35. Equities research analysts anticipate that Atara Biotherapeutics will post ($3.70) earnings per share for the current fiscal year.

Your IP Address:

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Stock Ratings for Atara Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc and related stocks with our FREE daily email newsletter.